Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03059485 · ClinicalTrials.gov registry record · Phase 2
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
A Phase 2 study of Acute Myelogenous Leukemia, sponsored by Beth Israel Deaconess Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 4
- Study locations
NCT03059485 is a Phase 2 study of Acute Myelogenous Leukemia that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 82 participants, below the 138-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (41% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT03059485, a Phase 2 study of Acute Myelogenous Leukemia, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: -Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)
Conditions Studied
Interventions
- OTHER Observation
- BIOLOGICAL DC/AML Fusion Vaccine
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2026-12-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03059485
The ClinicalTrials.gov registry entry for NCT03059485 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 138-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (41% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myelogenous Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Observation is the first listed.
NCT03059485 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03059485 about?
NCT03059485 is a clinical study titled "DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission". This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: -Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)
What is the current status of trial NCT03059485?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2017-06-01. Estimated completion is 2026-12-04.
What conditions does trial NCT03059485 study?
This clinical trial studies the following conditions: Acute Myelogenous Leukemia.
What interventions are being tested in trial NCT03059485?
The interventions under investigation include: Observation (OTHER), DC/AML Fusion Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03059485?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03059485 being conducted?
This trial has 4 study locations across Massachusetts, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myelogenous Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
RECRUITING · Phase 2
-
Allo HSCT Using RIC and PTCy for Hematological Diseases
RECRUITING · Phase 2
-
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)
COMPLETED · Phase 2
-
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.